Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Merck
Cerilliant
Chubb
McKesson
Teva
Argus Health
Novartis
Julphar
Harvard Business School

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 065380

« Back to Dashboard

NDA 065380 describes SUPRAX, which is a drug marketed by Lupin Ltd, Lederle, and Lupin Pharms, and is included in eight NDAs. It is available from five suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the SUPRAX profile page.

The generic ingredient in SUPRAX is cefixime. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the cefixime profile page.
Summary for 065380
Tradename:SUPRAX
Applicant:Lupin Ltd
Ingredient:cefixime
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 065380
Ingredient-typeCephalosporins
Medical Subject Heading (MeSH) Categories for 065380
Suppliers and Packaging for NDA: 065380
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SUPRAX cefixime TABLET, CHEWABLE;ORAL 065380 ANDA LUPIN PHARMA 27437-203 27437-203-11 1 BLISTER PACK in 1 CARTON (27437-203-11) > 10 TABLET, CHEWABLE in 1 BLISTER PACK
SUPRAX cefixime TABLET, CHEWABLE;ORAL 065380 ANDA LUPIN PHARMA 27437-203 27437-203-10 10 TABLET, CHEWABLE in 1 BOTTLE (27437-203-10)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, CHEWABLE;ORALStrength100MG
Approval Date:Oct 25, 2010TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, CHEWABLE;ORALStrength150MG
Approval Date:Oct 25, 2010TE:RLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, CHEWABLE;ORALStrength200MG
Approval Date:Oct 25, 2010TE:RLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Cantor Fitzgerald
Fish and Richardson
Queensland Health
Cerilliant
Daiichi Sankyo
Farmers Insurance
Medtronic
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot